The prognostic significance of Ki-67 labeling indices for oligodendrogliomas

Neurosurgery

Volumn 41, Issue 4, 1997, Pages 878-885

  Coons, Stephen W ^a   Johnson, Peter C ^a   Pearl, Dennis K ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Histological grade; Ki 67; MIB 1; Oligodendroglioma; Proliferation; Survival

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN; BRAIN NEOPLASMS; CELL DIVISION; FEMALE; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030820140     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199710000-00021     Document Type: Article

References (53)

1. Allegranza A, Girlando S, Arrigoni GL, Veronese S, Mauri FA, Gambacorta M, Pollo B, Palma PD, Barbareschi M: Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch A Pathol Anat Histopathol 419:417-423, 1991.
2. Ang LC, Plewes M, Tan L, Begley H, Agranovich A, Shul D: Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 21:306-310, 1994.
3. Barbareschi M, Girlando S, Mauri FM, Forti S, Eccher C, Mauri FA, Togni R, Dalla Palma P, Doglioni C: Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 102:171-175, 1994.
4. Bruner JM: Oligodendroglioma: Diagnosis and prognosis. Semin Diagn Pathol 4:251-261, 1987.
5. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE: Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345-1352, 1987.
6. Burger PC, Scheithauer BW, Vogel FS: Brain tumors, in Surgical Pathology of the Nervous System and Its Coverings. New York, Churchill Livingstone, 1991, pp 193-437.
7. Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: Application to surgical neuropathology. Am J Surg Pathol 10:611-617, 1986.
8. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56:1106-1111, 1985.
9. Coons SW, Johnson PC: Regional heterogeneity in the DNA content of human gliomas. Cancer 72:3052-3060, 1993.
10. Coons SW, Johnson PC: Regional heterogeneity in the proliferarive activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 52:609-618, 1993.
11. Coons SW, Johnson PC, Pearl DK: Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human astrocytomas. Neurosurgery 35:119-126, 1994.
12. Coons SW, Johnson PC, Pearl DK, Olafsen AG: Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human oligodendrogliomas. Neurosurgery 34:680-687, 1994.
13. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas: A simple and reproducible method. Cancer 62: 2152-2156, 1988.
14. Deckert M, Reifenberger G, Wechsler W: Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 115:179-188, 1989.
15. Earnest F III, Kernohan JW, Craig WM: Oligodendrogliomas: A review of two hundred cases. Arch Neurol Psychiatry 63:964-976, 1950.
16. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: An immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry 59:413-419, 1995.
17. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984.
18. Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, Stein H: Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol (Berl) 74:179-182, 1987.
19. Going JJ: Efficiently estimated histologic cell counts. Hum Pathol 25:333-336, 1994.
20. Heegaard S, Sommer HM, Broholm H, Braendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76:1809-1813, 1995.
21. Hepburn PJ, Glynne-Jones E, Goddard L, Gee JM, Harper ME: Cell proliferation in prostatic carcinoma: Comparative analysis of Ki-67, MIB-1 and PCNA. Histochem J 27:196-203, 1995.
22. Hopf NJ, Bremm J, Bohl J, Perneczky A: Image analysis of proliferating cells in tumors of the human nervous system: An immunohistological study with the monoclonal antibody Ki-67. Neurosurgery 35:917-923, 1994.
23. Hoshino T: Cell kinetics of glial tumors. Rev Neurol (Paris) 148:396-401, 1992.
24. Hoyt JW, Gown AM, Kim DK, Berger MS: Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 24:163-169, 1995.
25. Kalbfleitch JD: The Statistical Analysis of Failure Times. New York, Wiley and Sons, 1980.
26. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T: Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB1 monoclonal antibody on archival material. Acta Neuropathol (Berl) 87:47-54, 1994.
27. Karkavelas G, Mavropoulou S, Fountzilas G, Christoforidou V, Karavelis A, Foroglou G, Papadimitriou C: Correlation of proliferating cell nuclear antigen assessment, histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res 15:531-536, 1995.
28. Kernohan JW, Mabon RF, Svien HJ, Adson AW: A simplified classification of the gliomas. Proc Staff Meet Mayo Clin 24:71-75, 1949.
29. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system, in Kleihues P, Burger PC, Scheithauer BW (eds): International Histological Classification of Tumours. Geneva, Switzerland, World Health Organization, 1995.
30. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78:1107-1113, 1996.
31. Kros JM, Troost D, Van Eden CG, van der Werf JM, Uylings HBM: Oligodendroglioma: A comparison of two grading systems. Cancer 61:2251-2259, 1988.
32. Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH: Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66:1204-1212, 1990.
33. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study. Acta Neuropathol (Berl) 81:675-679, 1991.
34. Mazerolles C, Rishmann P, Chopin D, Popov Z, Malavaud B, Selves J, Neulat-Duga I, Bellot J, Delsol G: Usefulness of MIB1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: Comparison with Ki-67 antibody. Histopathology 25:563-568, 1994.
35. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns BJ, Burger PC: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34:674-678, 1994.
36. Mørk SJ, Halvorsen TB, Lindegaard K-F, Eide GE: Oligodendroglioma: Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65-78, 1986.
37. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T: Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74:1921-1926, 1994.
38. Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P: The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours. Acta Neurochir (Wien) 89:117-121, 1987.
39. Patsouris E, Stocker U, Kallmeyer V, Keiditsch E, Mehraein P, Stavrou D: Relationship between Ki-67 positive cells, growth rate and histological type of human intracranial tumors. Anticancer Res 8:537-544, 1988.
40. Pich A, Ponti R, Valente G, Chiusa L, Geuna M, Novero D, Palestro G: MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol 47:18-22, 1994.
41. Pigott TJ, Lowe JS, Palmer J: Statistical modelling in analysis of prognosis in glioblastoma multiforme: A study of clinical variables and Ki-67 index. Br J Neurosurg 5:61-66, 1991.
42. Remmele W, Muhlfait V, Keul HG: Estimation of the proliferate activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies: Comparative studies on frozen and paraffin sections. Virchows Arch A Pathol Anat Histopathol 426:435-439, 1995.
43. Ringertz N: "Grading$ of gliomas. Acta Pathol Microbiol Scand 27:51-64, 1950.
44. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS Isola JJ, Helin HJ: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275-282, 1994.
45. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH: Mixed oligoastrocytomas: A survival and prognostic factor analysis. Neurosurgery 34:577-582, 1994.
46. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 76:428-434, 1992.
47. Shibata T, Burger PC, Kleihues P: Ki-67 immunoperoxidase stain as marker for the histological grading of nervous system tumours. Acta Neurochir Suppl (Wien) 43:103-106, 1988.
48. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW: Grading of Oligodendrogliomas. Cancer 52:2107-2114, 1983.
49. Svien HJ, Mabon RF, Kernohan JW, Adson AW: Astrocytomas. Proc Staff Meet Mayo Clin 24:54-63, 1949.
50. Theunissen PH, Blaauw G: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology 23:75-79, 1993.
51. Vigliani MC, Chiò A, Pezzulo T, Soffietti R, Giordana MT, Schiffer D: Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: Its prognostic significance. Tumori 80:295-300, 1994.
52. Wacker M, Hoshino T, Ahn D, Davis R, Prados M: The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas. J Neurooncol 19:113-122, 1994.
53. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S Tamaki M, Hirakawa K: Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77:373-380, 1996.